Table 6.

Correlation of increased nights of CAP_A2+A3(Norm) ≤ 33% with VLD CBP improvements on FM symptoms and sleep EEG measures.

	VLD CBP		Placebo
	CAP_A2+A3(Norm) Correlation		CAP_A2+A3(Norm) Correlation
Variable	r	p	r	p
Musculoskeletal pain	0.036	0.888	–0.091	0.719
Fatigue	0.617	0.006^†	–0.466	0.051
Dolorimetry	0.036	0.888	0.341	0.166
HAD score	0.505	0.033^†	–0.196	0.435
HAD depression subscore	0.556	0.017^†	–0.276	0.267
Patient-rated change in fatigue	0.614	0.007^†	–0.073	0.773
Clinician-rated change in fatigue	0.582	0.011^†	0.288	0.247
Total time awake, h	0.072	0.777	–0.551	0.018^†
Total sleep time, h	0.228	0.364	0.552	0.018^†
Stage 1, %	–0.036	0.413	0.206	0.413
Stage 2, %	–0.012	0.963	–0.525	0.025^†
Stage 3, %	0.179	0.477	0.160	0.526
Stage 4, %	0.072	0.777	0.161	0.524
REM, %	–0.096	0.706	0.480	0.044^†
Sleep efficiency, %	–0.179	0.477	0.662	0.003^†

↵† p ≤ 0.05. CAP: cyclic alternating pattern; HAD: Hospital Anxiety and Depression Scale.